# A Phase l Study to Evaluate the Pharmacokinetics and Safety Pasireotide in Subjects With Varying Degrees of Renal Impairment Compared to Healthy Volunteers

> **NCT01578928** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 50 (actual)

## Conditions studied

- Renal Impairment

## Interventions

- **DRUG:** SOM230

## Key facts

- **NCT ID:** NCT01578928
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05
- **Primary completion:** 2014-05
- **Final completion:** 2014-05
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2020-12-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01578928

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01578928, "A Phase l Study to Evaluate the Pharmacokinetics and Safety Pasireotide in Subjects With Varying Degrees of Renal Impairment Compared to Healthy Volunteers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01578928. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*